NeoMed

NeoMed

NeoMed was established in 2013 by James Burt, a former partner at a European life sciences investment firm. The firm operates from Jersey in the Channel Islands and invests solely in healthcare, targeting therapeutics, medical devices, diagnostics, and health technology businesses. Its investment scope spans pre-clinical proof-of-concept through to commercial-stage companies, with an emphasis on European and transatlantic opportunities. NeoMed deploys capital through a concentrated direct investment model, typically leading or co-leading early-stage and growth rounds. The firm has backed companies developing novel drug platforms, advanced interventional devices, and diagnostic tools aimed at unmet medical needs. Its geographic focus bridges Europe and the United States, with portfolio companies often pursuing regulatory pathways at both the EMA and FDA. NeoMed invests from a single pool of committed capital raised from institutional investors and family offices, structured as a conventional private equity fund rather than an open-ended vehicle. The firm maintains a limited number of active positions, enabling deep engagement with management teams on clinical trial design, regulatory strategy, and market access. NeoMed's structural differentiator is its pure-play life sciences mandate delivered through a small-portfolio, high-conviction model. Unlike diversified healthcare funds that spread across services, IT, and devices, NeoMed concentrates on a narrow set of companies where scientific risk is the primary variable, requiring principal-level expertise in translational medicine rather than generalist financial engineering.